Active substance: glucose
Injectio Glucosi 10% Baxter is a sugar (glucose) solution in water. Glucose is one of the body's energy sources. This infusion solution provides 400 kilocalories per liter. Injectio Glucosi 10% Baxter is used:
If another medicine is added to the infusion solution, always read the leaflet included with the packaging of that medicine. This will allow the patient to check if they can safely use the medicine.
Injectio Glucosi 10% Baxter is a hypertonic solution (concentrated). The doctor will take this into account when calculating the amount of solution to be administered to the patient. The patient should inform the doctor if they have or have had any of the following medical conditions:
During the administration of this solution to the patient, the doctor will check:
The doctor will decide how much of the infusion solution to administer to the patient based on the results of these tests. The tests will also provide the doctor with information on the need to administer potassium to the patient. If necessary, it can be administered intravenously. Since Injectio Glucosi 10% Baxter contains sugar (glucose), it may cause an increase in blood sugar levels (hyperglycemia). In such a situation, the doctor may:
This is especially important:
Do not administer this solution through the same needle as a blood transfusion. This may cause red blood cell breakdown or clumping.
Injectio Glucosi 10% Baxter should be administered with caution in children. Children should only be administered Injectio Glucosi 10% Baxter by a doctor or nurse. The dose to be administered will be decided by a doctor experienced in treating children and will depend on the child's age, weight, and condition. If Injectio Glucosi 10% Baxter is used to provide or dilute another medicine, or if other medicines are administered at the same time, this may also affect the dose. During infusion in children, the doctor will take blood and urine samples to monitor the levels of electrolytes in the blood, such as potassium (electrolytes in serum). Newborns, especially premature and low-birth-weight infants, are more susceptible to hypoglycemia or hyperglycemia and should be closely monitored during treatment with intravenous glucose solutions to ensure proper blood sugar control and avoid potential long-term side effects. Low blood sugar in newborns can cause prolonged seizures, coma, and brain damage. High blood sugar levels are associated with brain hemorrhage, bacterial or fungal infection, vision damage (retinopathy of prematurity), gastrointestinal infections (necrotizing enterocolitis), lung disorders (bronchopulmonary dysplasia), prolonged hospital stay, and death. When administering to newborns, the solution bag can be connected to an infusion pump, which will allow for the administration of the required amount of solution at set time intervals. The doctor or nurse will monitor the device to ensure safe administration. In children (including newborns and older children) receiving Injectio Glucosi 10% Baxter, there is a higher risk of developing low sodium levels in the blood (hypotonic hyponatremia) and brain disorders due to low sodium levels in the serum (hyponatremic encephalopathy).
Tell the doctor or nurse about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take. Injectio Glucosi 10% Baxter and other medicines taken at the same time may interact with each other. Do not take Injectio Glucosi 10% Baxter with certain hormones (catecholamines), including adrenaline or steroids, as they may cause an increase in blood sugar levels. Some medicines may affect vasopressin hormone levels. These include:
Ask the doctor what can be eaten or drunk.
If the patient is pregnant or breastfeeding, or thinks they may be pregnant or plans to have a child, they should consult a doctor or nurse before using this medicine.
Glucose solution may be used during pregnancy. However, caution should be exercised when administering glucose to a patient during labor.
There is no relevant data on the effect of glucose on fertility. However, it is not expected to affect fertility.
There is no relevant data on the use of glucose solution in breastfeeding women. However, it is not expected to affect breastfeeding women. Glucose solution may be used during breastfeeding. Before adding any medicine to the Injectio Glucosi 10% Baxter solution used during pregnancy or breastfeeding, the patient should:
Consult a doctor or nurse before driving or operating machines.
Injectio Glucosi 10% Baxter is administered by a doctor or nurse. The dose and duration of administration will be decided by the doctor. This will depend on the patient's age, weight, health status, and reason for treatment. The dose may also be affected by other medicines being taken at the same time.
Injectio Glucosi 10% Baxter is usually administered through a plastic tube connected to a needle inserted into a vein. Typically, an arm vein is used for infusion. However, the doctor may use a different method to administer this medicine. Before and during infusion, the doctor will monitor:
Any unused solution should be discarded. DO NOT administer Injectio Glucosi 10% Baxter from a partially used bag.
Administration of too much Injectio Glucosi 10% Baxter (overdose) or administration too quickly or too frequently may cause the following symptoms:
If any of these symptoms occur, the doctor should be informed immediately. The doctor will stop or reduce the infusion. Insulin and appropriate treatment will be administered depending on the symptoms. If another medicine was added to the Injectio Glucosi 10% Baxter infusion before the overdose symptoms occurred, it may also be the cause of the symptoms. The patient should read the leaflet included with the packaging of the added medicine to learn about possible symptoms.
The decision to discontinue Injectio Glucosi 10% Baxter is made by the doctor. In case of doubts about the use of the medicine, the patient should consult a doctor or nurse.
Like all medicines, Injectio Glucosi 10% Baxter can cause side effects, although not everybody gets them. Side effects may include:
If another medicine is added to the infusion solution, it may also cause side effects. These side effects will depend on the added medicine. The patient should read the leaflet included with the packaging of the added medicine to learn about possible symptoms. If any side effects occur, the infusion should be stopped. If the patient experiences any side effects, including any side effects not listed in this leaflet, they should inform their doctor or nurse.
If side effects occur, including any side effects not listed in this leaflet, the doctor or nurse should be informed. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, PL 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, e-mail: ndl@urpl.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children. There are no special precautions for the storage of this medicinal product. DO NOT use Injectio Glucosi 10% Baxter after the expiration date stated on the bag and carton, after the "Expiration Date" section. The expiration date refers to the last day of the specified month. DO NOT administer Injectio Glucosi 10% Baxter if it contains visible particles or if the packaging is damaged in any way.
The active substance is glucose (in the form of glucose monohydrate): 100 g per liter. The only other ingredient is water for injections. Composition per 250 ml: Glucose (in the form of glucose monohydrate): 25 g. Composition per 500 ml: Glucose (in the form of glucose monohydrate): 50 g. Composition per 1000 ml: Glucose (in the form of glucose monohydrate): 100 g.
Injectio Glucosi 10% Baxter is a clear solution, free from visible particles. It is available in polyolefin/polyamide plastic bags (Viaflo). Each bag is placed in a closed, protective, outer plastic packaging. Bag sizes:
Package sizes:
Not all pack sizes may be marketed.
Marketing authorization holder: Baxter Polska Sp. z o.o., Ul. Kruczkowskiego 8, 00-380 Warsaw. Manufacturer: Bieffe Medital S.A., Ctra de Biescas, Senegüé, 22666 Sabiñanigo (Huesca), Spain. Date of last revision of the leaflet:20.03.2019. Baxter and Viaflo are trademarks of Baxter International Inc.
Before administration, the infusion solution should be visually inspected. Products for parenteral administration should be inspected for visible particles or discoloration, if the solution and packaging allow. Use only if the solution is clear, free from visible particles, and the packaging is undamaged. Administer immediately after connecting the infusion set.
Plastic containers should not be connected in series. Such use could cause an air embolism, caused by residual air drawn into the first container before the fluid is completely administered from the second container. Applying additional pressure on intravenous solutions contained in flexible plastic containers to increase the flow rate may cause an air embolism if the container is not completely emptied of air before administration. The use of infusion sets with air vents, with the air vent valve in the open position, may cause an air embolism. Do not use infusion sets with air vents, with the air vent valve in the open position, with flexible plastic containers. The solution should be administered using sterile equipment and aseptic technique. The infusion equipment should be primed with the solution before administration to prevent air from entering the system. Electrolyte supplementation may be indicated based on the patient's clinical needs. Additional medicines can be added to the solution before or during infusion through the self-sealing port for adding medicines. When using another medicine, the final osmolality of the solution should be confirmed before parenteral administration. It is essential to carefully and cautiously mix the solution with any additional medicine under aseptic conditions. Solutions containing added medicines should be used immediately, without storage.
Use sterile materials for preparation and administration.
Warning: Added medicines may be incompatible.
Adding medicines before administration
Adding medicines during administration
Before use, the chemical and physical stability of each added medicine should be established in the pH of Injectio Glucosi 10% Baxter in the Viaflo container. From a microbiological point of view, the diluted product should be used immediately, unless dilution is performed under controlled and validated aseptic conditions. If the solution is not used immediately, the user is responsible for the storage time and conditions during use.
Glucose solution should not be administered through the same infusion set as blood, before or after blood transfusion, as this may cause hemolysis and agglutination. Before adding a medicine, its compatibility with the solution in the Viaflo container should be evaluated. In the absence of compatibility studies, this solution should not be mixed with other medicines. Read the instructions for use of the medicine to be added. Before adding a medicine, check if it is soluble and stable in water at the pH of Injectio Glucosi 10% Baxter (pH 3.5 to 6.5). After adding a compatible medicine to Injectio Glucosi 10% Baxter, the solution should be administered immediately. Do not use medicines known to be incompatible. Baxter and Viaflo are trademarks of Baxter International Inc.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.